News
Sermonix Shares Two Recently Presented Posters Evaluating ESR1 Mutations in Circulating Tumor DNA From Patients With ER+/HER2- Metastatic Breast Cancer Who Were Treated With Lasofoxifene
Posters were presented Dec. 9 at the San Antonio Breast Cancer Symposium (SABCS) One abstract...
Sermonix Shares Two Posters at SABCS 2022 on ER+/HER2- Metastatic Breast Cancer Patient Survey About Knowledge of NGS and ESR1 Mutations, Quality of Life Concerns
SAN ANTONIO, Dec. 09, 2022 (GLOBE NEWSWIRE) -- Sermonix Pharmaceuticals Inc., a privately held...
Sermonix Pharmaceuticals Announces Poster Presentation on Phase 1 Ethnobridging Study of Lasofoxifene at the 12th AACR-JCA Joint Conference: Breakthroughs in Cancer Research — Translating Knowledge Into Practice
COLUMBUS, Ohio, Dec. 08, 2022 (GLOBE NEWSWIRE) -- Sermonix Pharmaceuticals Inc., a privately held...
Sermonix Pharmaceuticals Announces Four Abstracts Accepted for Presentation at 2022 San Antonio Breast Cancer Symposium
COLUMBUS, Ohio, Nov. 17, 2022 (GLOBE NEWSWIRE) -- Sermonix Pharmaceuticals Inc., a privately held...
Sermonix Pharmaceuticals Shares Details of First-Ever Known Durable Complete Clinical Response in a Metastatic ER+/HER2- Breast Cancer Patient With an ESR1 Mutation After Prior CDK4/6 Inhibitor Treatment Via Single-Agent Hormonally Based Regimen
COLUMBUS, Ohio, Sept. 14, 2022 (GLOBE NEWSWIRE) -- Sermonix Pharmaceuticals Inc., a privately held...
Sermonix Pharmaceuticals Announces Results of Phase 2 Study of Lasofoxifene vs. Fulvestrant in Postmenopausal Women With Locally Advanced or Metastatic ER+/HER2- Breast Cancer and an ESR1 Mutation
COLUMBUS, Ohio, Sept. 13, 2022 (GLOBE NEWSWIRE) — Sermonix Pharmaceuticals Inc., a privately held...
Sermonix Pharmaceuticals Announces Top-Line Data From ELAINE 1 Phase 2 Study of Lasofoxifene Versus Fulvestrant Is Accepted for a Late-Breaking Oral Presentation at ESMO Congress 2022
COLUMBUS, Ohio, Aug. 25, 2022 (GLOBE NEWSWIRE) — Sermonix Pharmaceuticals Inc., a privately held...
Sermonix to Host Virtual Clinical Update on its ELAINE Phase 2 Clinical Programs
COLUMBUS, June 09, 2022 (GLOBE NEWSWIRE) — Sermonix Pharmaceuticals Inc., a privately held...
Sermonix Pharmaceuticals’ Phase 2 Lasofoxifene Trial Poster Receives a GRASP Advocate Choice Award, Selected for Post-ASCO Patient Advocate Investigator Discussions
Guiding Researchers and Advocates to Scientific Partnerships (GRASP) launched in 2019 to unite...
To sign up for future Sermonix press releases, please enter your information below.